Westhouse Medical Services Plc Acquires Revolutionary Breast Scan Device Patents

LONDON, November 9, 2011 /PRNewswire/ --

New Technology to Complement Westhouse Medical's Breast Cancer Screening Product Development

New healthcare specialist Westhouse Medical Services Plc today announces the acquisition of revolutionary new breast cancer screening technology and patents.  The low cost, mobile and non-invasive device will provide the healthcare industry with a modern alternative to mammogram screening, and further supports Westhouse Medical's breast cancer screening product development.

Westhouse Medical purchased the US and UK patents for the Profemme breast cancer screening technology for £500,000 from the Battlebridge Group Limited.

Westhouse Medical, which consists of two divisions - Devices and Services, is a specialist company creating value for investors, providers and patients by delivering step changes in the effectiveness and quality of primary healthcare delivery. The company listed on the Open Standard Section of the Frankfurt Stock Exchange in late October 2011.

Westhouse's Medical Devices division identifies and develops innovative medical technologies, and the new cost-effective breast cancer screening technology is the first announcement from the division.

The breast cancer screening device uses thermometry-based technology to measure for temperature differences in breast tissue indicating any abnormalities and early symptoms of precursors to more serious conditions, including cancerous cells.  Upon detection, the patient can then be referred on for further professional analysis and diagnosis.  

Jack Kaye, chief executive for Westhouse Medical Services comments: "This acquisition is a valuable addition to the company's product portfolio, and complements our current work on the development of a low-cost thermometry- based breast cancer screening device, BreastCheck™, which will be available for both hospital and home use, meaning patients can self-test, further reducing the strain on already-stretched healthcare budgets and hospital staff."  

Kaye continues: "At present, there are few options available to the healthcare industry for breast cancer screening outside of mammograms. Whilst mammograms have formed the cornerstone of screening programmes for decades, they can be uncomfortable for the patient, expensive for healthcare providers and a drain of hospital resources, given the need for expert practitioners to administer tests.  

"Given the expense, some countries do not even have breast cancer screening programmes, whilst others are looking to reduce costs by raising the age at which testing takes place, or making screening less frequent. Westhouse Medical is developing a low cost alternative which will revolutionise the economics of testing by allowing for easy, regular testing which can start at a lower age. It means more women can be screened more often, which we hope will save more lives."

The acquisition of the new breast cancer screening patents by Westhouse Medical follows the recent launch of an independent review in the UK of the NHS breast cancer screening programme.  

About Westhouse Medical

Westhouse Medical Services Plc creates value for investors, providers and patients by delivering step changes in the effectiveness and quality of healthcare delivery.

Listed in the Open Section of the Frankfurt Stock Exchange  (Ticker code 5WM), Westhouse Medical is currently composed of two wholly-owned subsidiaries; Medical Services, providing specialist patient transfer and ambulance services; and Medical Devices, which is developing innovative new cost-effective healthcare technologies,  including new breast cancer screening devices.

Westhouse Medical Services PLC plans to grow through the acquisition and development of other leading medical businesses within Europe and North America, under the leadership of CEO Jack Kaye - who brings over 35 years of global technology and services business management expertise to the company.  

Westhouse Medical - Primary Healthcare Effectiveness Delivered.